Therapeutic Cancer Vaccines-T Cell Responses and Epigenetic Modulation

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2019 Feb 12

PMID 30740111

Citations 23

Authors

Apriliana E R Kartikasari

Monica D Prakash

Momodou Cox

Kirsty Wilson

Jennifer C Boer

Jennifer A Cauchi

Magdalena Plebanski

Affiliations

Soon will be listed here.

Abstract

There is great interest in developing efficient therapeutic cancer vaccines, as this type of therapy allows targeted killing of tumor cells as well as long-lasting immune protection. High levels of tumor-infiltrating CD8 T cells are associated with better prognosis in many cancers, and it is expected that new generation vaccines will induce effective production of these cells. Epigenetic mechanisms can promote changes in host immune responses, as well as mediate immune evasion by cancer cells. Here, we focus on epigenetic modifications involved in both vaccine-adjuvant-generated T cell immunity and cancer immune escape mechanisms. We propose that vaccine-adjuvant systems may be utilized to induce beneficial epigenetic modifications and discuss how epigenetic interventions could improve vaccine-based therapies. Additionally, we speculate on how, given the unique nature of individual epigenetic landscapes, epigenetic mapping of cancer progression and specific subsequent immune responses, could be harnessed to tailor therapeutic vaccines to each patient.

Citing Articles

Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy.

Megdiche Y, Salerno-Goncalves R Front Immunol. 2025; 16:1547213.

PMID: 40040700 PMC: 11876029. DOI: 10.3389/fimmu.2025.1547213.

Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment.

Chang Y, Chang M, Bao X, Dong C Bioact Mater. 2024; 42:379-403.

PMID: 39308543 PMC: 11415837. DOI: 10.1016/j.bioactmat.2024.08.046.

Chemoproteomics reveals immunogenic and tumor-associated cell surface substrates of ectokinase CK2α.

Delaveris C, Kong S, Glasgow J, Loudermilk R, Kirkemo L, Zhao F Cell Chem Biol. 2024; 31(9):1729-1739.e9.

PMID: 39178841 PMC: 11482644. DOI: 10.1016/j.chembiol.2024.07.018.

Evaluation of changes in exhausted T lymphocytes and miRNAs expression in the different trimesters of pregnancy in pregnant women.

Shekarchi A, Hosseini L, Kamrani A, Alipourfard I, Soltani-Zangbar M, Akbari M Mol Biol Rep. 2024; 51(1):442.

PMID: 38520563 DOI: 10.1007/s11033-024-09370-3.

Dendritic cell-targeted delivery of antigens using extracellular vesicles for anti-cancer immunotherapy.

Dang X, Phung C, Lim C, Jayasinghe M, Ang J, Tran T Cell Prolif. 2024; 57(7):e13622.

PMID: 38509634 PMC: 11216926. DOI: 10.1111/cpr.13622.

References

Kanaseki T, Ikeda H, Takamura Y, Toyota M, Hirohashi Y, Tokino T . Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas. J Immunol. 2003; 170(10):4980-5. DOI: 10.4049/jimmunol.170.10.4980. View

Kang J, Demaria S, Formenti S . Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer. 2016; 4:51. PMC: 5028964. DOI: 10.1186/s40425-016-0156-7. View

Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View

Foster S, Hargreaves D, Medzhitov R . Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature. 2007; 447(7147):972-8. DOI: 10.1038/nature05836. View

Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View

Kurts C, Robinson B, Knolle P . Cross-priming in health and disease. Nat Rev Immunol. 2010; 10(6):403-14. DOI: 10.1038/nri2780. View

Abdelsamed H, Zebley C, Youngblood B . Epigenetic Maintenance of Acquired Gene Expression Programs during Memory CD8 T Cell Homeostasis. Front Immunol. 2018; 9:6. PMC: 5778141. DOI: 10.3389/fimmu.2018.00006. View

Heeg K, Dalpke A, Peter M, Zimmermann S . Structural requirements for uptake and recognition of CpG oligonucleotides. Int J Med Microbiol. 2007; 298(1-2):33-8. DOI: 10.1016/j.ijmm.2007.07.007. View

Pearce E, Mullen A, Martins G, Krawczyk C, Hutchins A, Zediak V . Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science. 2003; 302(5647):1041-3. DOI: 10.1126/science.1090148. View

10.

Topfer K, Kempe S, Muller N, Schmitz M, Bachmann M, Cartellieri M . Tumor evasion from T cell surveillance. J Biomed Biotechnol. 2011; 2011:918471. PMC: 3228689. DOI: 10.1155/2011/918471. View

11.

Carreno B, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti A . Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015; 348(6236):803-8. PMC: 4549796. DOI: 10.1126/science.aaa3828. View

12.

Marcus A, Gowen B, Thompson T, Iannello A, Ardolino M, Deng W . Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol. 2014; 122:91-128. PMC: 4228931. DOI: 10.1016/B978-0-12-800267-4.00003-1. View

13.

Kim M, Ouyang W, Liao W, Zhang M, Li M . The transcription factor Foxo1 controls central-memory CD8+ T cell responses to infection. Immunity. 2013; 39(2):286-97. PMC: 3809840. DOI: 10.1016/j.immuni.2013.07.013. View

14.

Kemna E, Tjalsma H, Laarakkers C, Nemeth E, Willems H, Swinkels D . Novel urine hepcidin assay by mass spectrometry. Blood. 2005; 106(9):3268-70. DOI: 10.1182/blood-2005-05-1873. View

15.

Davis I, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W . Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A. 2004; 101(29):10697-702. PMC: 489997. DOI: 10.1073/pnas.0403572101. View

16.

Shin M, You S, Kang Y, Lee N, Yoo S, Park K . DNA Methylation Regulates the Differential Expression of CX3CR1 on Human IL-7Rαlow and IL-7Rαhigh Effector Memory CD8+ T Cells with Distinct Migratory Capacities to the Fractalkine. J Immunol. 2015; 195(6):2861-9. PMC: 4561204. DOI: 10.4049/jimmunol.1500877. View

17.

Magner W, Kazim A, Stewart C, Romano M, Catalano G, Grande C . Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol. 2000; 165(12):7017-24. DOI: 10.4049/jimmunol.165.12.7017. View

18.

Ghoneim H, Fan Y, Moustaki A, Abdelsamed H, Dash P, Dogra P . De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell. 2017; 170(1):142-157.e19. PMC: 5568784. DOI: 10.1016/j.cell.2017.06.007. View

19.

North S, Butts C . Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev Vaccines. 2005; 4(3):249-57. DOI: 10.1586/14760584.4.3.249. View

20.

Zhang X, Ulm A, Somineni H, Oh S, Weirauch M, Zhang H . DNA methylation dynamics during ex vivo differentiation and maturation of human dendritic cells. Epigenetics Chromatin. 2014; 7:21. PMC: 4144987. DOI: 10.1186/1756-8935-7-21. View